Nyreprofylakse ved ST-segment elevation myokardie infarkt og primær PCI

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-017642-32-DK

Enrollment

Unknown

Registered

2010-01-05

Start date

2010-02-16

Completion date

Unknown

Last updated

2021-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decreased renal function in patients with STEMI undergoing acute PCI

Interventions

Trade Name: Natriumbikarbonat Isotonisk "SAD" Product Name: Natriumbikarbonat Isotonisk Pharmaceutical Form: Solution for infusion INN or Proposed INN: Sodium Hydrogene carbonate Trade Name: Mucomyst

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: STEMI patients undergoing primary PCI Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Cardiogen shock or unconscious. Ventricular fibbrillation or cardiac arrest. Known maligncy or serious infection disease.

Design outcomes

Primary

Measure	Time frame
Main Objective: Change in se-creatinine day 0-3 following PCI;Secondary Objective: Change in se-creatinine day 3-30 Change in se-creatinine day 0-30;Primary end point(s): Change in se-ceatinine day 0-3	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026